1. Multiple sclerosis: Oral Therapies and Beyond

2. Treatment Algorithm for Pediatric Patients With MS

3. Diagnosis and Initiating Treatment

4. Pathophysiology of MS: Inflammation-Independent Neurodegeneration?

5. BVL in MS—Overview

6. Brain Volume Change: Under Multiple Influences

7. Some State-of-the-Art Technologies for Assessing Brain Atrophy in MS

8. Most Common Current Measures for Whole Brain and Regional Brain Atrophy

9. GM and WM Volume Changes in Early RRMS

10. GM Atrophy Is Related to Long-term Disability in RRMS

11. Treating RRMS: Immediate and Delayed Effects on Brain Volume

12. Fingolimod Effect on Diffuse Tissue Damage Is Partly Independent of Its Effect on Focal Damage in RRMS

13. Fingolimod Effects on DP Mediated by Effects on BVL

14. NEDA-4

15. Fingolimod on NEDA-4

16. How Does RWE Differ From RCT Data?

17. What Is Driving the Increased Demand for RWE?

18. Advantages of RWE

19. The Principles of Propensity Score Matching in Patients With MS

20. Propensity Matching to Identify Matched Populations in MS

21. Comparative Effectiveness of GA and IFNβ Formulations in RRMS

22. MSBase: Switch to Fingolimod vs BRACE Therapies

23. MSBase: Switch to Fingolimod vs Natalizumab

24. Epidemiology of PPMS

25. Compartmentalized Inflammation in Progressive MS

26. DMTs in PPMS: Long History of Negative Trial Results

27. INFORMS: Fingolimod in PPMS

28. ORATORIO: Ocrelizumab in PPMS

29. Anti-inflammatory Properties of Fingolimod[a] and Ocrelizumab[b]: Lessons From RRMS Primary 24-Week Data

30. INFORMS[a] vs ORATORIO[b]: Differences in Patient Population

31. MS-SPI: MD1003 (High-Dose Biotin) in Progressive MS

32. MD1003: Mechanisms of Action

33. ORATORIO: Anti-inflammatory Effect of Ocrelizumab

34. SPRINT-MS Trial: Exploring Imaging Biomarkers

35. ARPEGGIO: Laquinimod in PPMS

36. Abbreviations

37. Abbreviations (cont)

38. Abbreviations (cont)